Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer

SIMPLE SUMMARY: Trastuzumab and radiation are used clinically to treat HER2-overexpressing breast cancers; however, the mechanistic synergy of anti-HER2 and radiation therapy has not been investigated. In this study, we identify that a subtherapeutic dose of trastuzumab sensitizes the tumor microenv...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Patrick N., Mansur, Ameer, Lu, Yun, Della Manna, Deborah, Burns, Andrew, Samuel, Sharon, Heinzman, Katherine, Lapi, Suzanne E., Yang, Eddy S., Sorace, Anna G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869800/
https://www.ncbi.nlm.nih.gov/pubmed/35205763
http://dx.doi.org/10.3390/cancers14041015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869800/
https://www.ncbi.nlm.nih.gov/pubmed/35205763
http://dx.doi.org/10.3390/cancers14041015

Ejemplares similares